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The motivation to modify the design of a vascular device can arise from a number of sources. Clinical experience with the
unmodiﬁed device could suggest new design modiﬁcations to improve device performance or clinical outcomes. Similarly,
clinical success with a device often suggests modiﬁcations that could broaden the applicability of the device to enable
treatment of different or more advanced disease states. As a speciﬁc example, both of these scenarios have arisen during
the last decade in the evolution of endovascular grafts for the treatment of abdominal aortic aneurysms, with modiﬁ-
cations enabling the treatment of patients with shorter infrarenal necks, more angulated anatomy, and smaller access
vessels. These modiﬁcations have been made by manufacturers and additionally by physicians who create branched and
fenestrated devices. The experience to date with the use of fenestrated devices and the development of chimney, snorkel,
and periscope techniques suggests that modiﬁcations to off-the-shelf devices may provide some clinical beneﬁt. This
experience provides additional motivation for manufacturers to develop devices to address the clinical needs not met with
their current product lines. For manufacturers, the device development process includes an assessment of the new device
design to determine the appropriate evaluation strategy to support the safety and effectiveness of the modiﬁed device. This
report provides a high-level overview of the process generally followed by device manufacturers to evaluate a proposed
device modiﬁcation before market release, in accordance with local country regulations and recognized international
standards such as the International Organization of Standardization (ISO) standards for endovascular grafts (ISO 25539
Part 1). (J Vasc Surg 2013;57:826-8.)Device manufacturers aim to provide high-quality
products to enable their physician customers to achieve
good clinical outcomes for their patients while complying
with the appropriate regulatory requirements applicable
to the speciﬁc region. Both of these objectives are served
by using a structured and comprehensive process to eval-
uate proposed changes to a device before commercial
introduction. This report provides a high-level overview
of the process generally followed by device manufacturers
to evaluate a proposed device modiﬁcation before market
release, in accordance with local country regulations and
recognized international standards such as the Interna-
tional Organization of Standardization (ISO) standards
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DESIGN MODIFICATION
Modiﬁcation description. The ﬁrst step in evaluating
a potential design modiﬁcation to a vascular device is to
describe and document the modiﬁcation and the reasons
why such a modiﬁcation may be warranted (ie, describe
the anticipated performance and patient beneﬁts). This
documentation usually includes an engineering description
of the proposed modiﬁcations and a description of the
other relevant aspects of the design (including potential
speciﬁcations), the intended patient population (high-
lighting any differences from the currently served popula-
tion), and appropriate ranges of anatomy, such as aortic
diameters and neck lengths, to be treated with the modi-
ﬁed device.
Risk analysis. Taking into consideration the intended
modiﬁcation and patient population, a risk analysis is per-
formed to identify failure modes that could be associated
with the proposed modiﬁcations.2,3 Some of the failure
modes will be similar to those for the unmodiﬁed device, so
the analysis tends to begin with a complete review of the
original risk analysis, with consideration of whether the
modiﬁcations may change the potential likelihood or
severity of the risks. For example, when adding branches to
an endograft, there could be migration between aortic
components, a potential risk with the unmodiﬁed device,
but which could be more clinically relevant if the migration
was also associated with occlusion of a branch vessel. Other
potential failure modes speciﬁc to the modiﬁed device or
differences in the patients to be treated would need to
be added to the analysis. An example of a new risk would
be the potential for the separation between an aortic
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requires answering a number of important questions, such
as:
d Will the modiﬁed device treat a different patient popu-
lation than the original device?
d If so, is the range of anatomic parameters in the new
patient population different from the anatomic param-
eter ranges of the original device?
d Might any anatomic differences affect device deploy-
ment behavior or implant durability, such as fatigue,
wear, or erosion?
d What potential new failure modes could occur with the
modiﬁed device? What is the likelihood of occurrence
for each of the new failure modes? If one of these
failure modes does occur, what would be the resulting
clinical effect on the patient?
d Are there new technical considerations for deployment
that require changes to the Instructions for Use or
device training, or both?
Performance information from the clinical use of other
device designs and information obtained with the use of
physician-modiﬁed devices under physician-sponsored In-
vestigational Device Exemptions (IDEs) may be used to
complete the risk analysis by providing information to
answer these questions. The resulting risk analysis is used
to reﬁne design speciﬁcations and to form the roadmap
for the subsequent evaluation and evolution of the device
modiﬁcation.
Data requirements. Once the updated risk analysis
has been completed, the scope of the proposed modiﬁca-
tions can be fully appreciated and a comprehensive test
plan created. The objective of this test plan is to identify
the data necessary to support conclusions that each of the
identiﬁed failure modes has an acceptable level of risk and
that there are sufﬁcient data to verify that the modiﬁed
device design will perform as intended. These data may
also conﬁrm the speciﬁcation changes for the modiﬁed
device design.
Establishment of the comprehensive test plan typically
involves identifying the required computer simulations and
testing (bench or animal) to evaluate the likelihood and
severity of each failure mode identiﬁed in the risk analysis.
Once this test plan has been created, it is important to
consider to what extent test data from the unmodiﬁed
device can be used to support conclusions on the modiﬁed
device. This will involve an assessment of the potential for
the device modiﬁcation to affect the study results. If the
change would not affect the results, the prior testing can
be leveraged. It may also be necessary to complete some
amount of testing on the original and modiﬁed device to
conﬁrm that the results are similar to those obtained for
the original unmodiﬁed device.
New test methods often must be implemented for
modiﬁed devices as manufacturers and physicians learn
more about the performance of existing devices. Increased
understanding of the underlying disease state may also leadto the need for new types of testing to better simulate
performance in vivo. The need for any new testing
methods would be identiﬁed through the completed risk
assessment. It may be appropriate to apply any updated
testing methods to the original design if comparisons are
needed to fully assess the potential failure mode.
Recent advancements in simulation technology are
increasingly enabling comparisons to be made between
the modiﬁed and unmodiﬁed devices through computer
analysis combined with physical testing and should be
considered in establishing the testing plan. The required
testing on the modiﬁed device may be simple, such as
a tensile test, or complex, such as a simulated 10-year dura-
bility test requiring sophisticated test equipment and
months to complete. Additional biocompatibility testing
may be required if new materials or processes are involved.
Device evaluation. The next step is to conduct the
testing on the modiﬁed device according to the test plan,
with comparisons to the unmodiﬁed device, as appropriate.
This testing may also include clinical studies, depending
on the data needed to fully evaluate each potential fail-
ure mode. Nonclinical testing of an implant change may
require many months and many hundreds of thousands
of dollars to complete; if clinical studies are required, the
scope typically extends to years and millions of dollars.
This comprehensive process for the evaluation of device
modiﬁcations is intended to provide the physician a reason-
able assurance of the safety and effectiveness of the modi-
ﬁed device.4
An example: Modiﬁcation of a device material. The
United States Food and Drug Administration (FDA)
approved for an endovascular stent graft system for the
treatment of infrarenal abdominal aortic or aortoiliac
vessels. The manufacturer modiﬁed the physical character-
istics of the material used in the manufacture of the stent
graft to enhance the robustness of the graft material. The
modiﬁed material had the same chemical composition as
the original material; however, the weaving process was
changed to achieve a denser weave conﬁguration. A risk
analysis was completed and used to establish an appropriate
testing strategy. Bench testing, including dimension veriﬁ-
cation, joint strength, burst strength, tensile strength,
fatigue, and water permeability, was needed on the modi-
ﬁed device to demonstrate that the new weaving process
did not adversely affect the physical performance properties
of the device. Animal testing was also needed to compare
vessel healing and patency of the new material with the
material used in the original device. Preclinical testing,
including animal testing, was adequate to demonstrate
a reasonable assurance of the safety and effectiveness of
the device.
An example: Modiﬁcation based on clinical use of
a device. An FDA-approved off-the-shelf stent graft indi-
cated for the treatment of descending thoracic aneurysm
disease in zones 2 and 3 has been used in an off-label
manner to allow for the treatment of more extensive
aortic disease. To treat disease that has progressed into
zones 0 or 1, the device has been deployed in conjunction
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allow for perfusion of the brachiocephalic artery. On the
basis of this usage, the device manufacturer modiﬁed its
device to include a branching component for this indica-
tion. A risk analysis was completed and an appropriate
testing strategy identiﬁed. Given the complex interactions
of the vessels and branching device, extensive computer
simulations, bench testing, animal studies, and clinical
studies were needed to provide a reasonable assurance of
safety and effectiveness, including the long-term durability
of the modiﬁed device.
REGULATORY SUBMISSION
From a device-evaluation perspective, the ﬁnal step to
bring a modiﬁed device to market is obtaining the appro-
priate regulatory approvals. Although the speciﬁcs of this
process vary by locale, it generally requires the manufac-
turer to create a comprehensive data package documenting
each of the above steps in detail, including:
d The updated risk analysis;
d The associated test plan;
d The technical details of how bench tests were per-
formed, including what constituted acceptable results;
d Protocols for any animal studies or clinical studies, or
both, that were performed;
d The results that were obtained from the testing; and
d The conclusions that were drawn from those results.
This comprehensive submission package is reviewed by
those with expertise in various technical areas at the regu-
latory agency, and a question and response period with
the manufacturer typically follows. Once the regulatory
agency determines that sufﬁcient information has been
provided, the appropriate clearance is granted and the
manufacturer may then bring the modiﬁed device to
market. As mentioned previously, these data might include
an extensive clinical evaluation depending on the magni-
tude of the modiﬁcation to the design. When a clinical
evaluation is deemed necessary, extensive review of the
bench-top testing and preclinical evaluations is usually
undertaken in the same manner as described above, before
the initiation of the clinical study.
POSTMARKET EVALUATIONS
Device testing does not necessarily end with the release
of a product to the market. Manufacturers may continue
evaluating device performance as new information
regarding the use of the device in the ﬁeld is gathered.
This can include further reﬁnement and validation of bench
test methods to better represent the observed clinicalperformance of devices, as well as evaluation of potential
observed failure modes. This information is in turn used
to continually improve the next generation of devices.
CONCLUSIONS
Device modiﬁcations may be motivated by a need to
improve performance or clinical outcomes, or both, or by
an opportunity to expand the applicability of a device to
more advanced disease or a new patient population. The
process for evaluation of device modiﬁcations by a manufac-
turer is comprehensive and follows guidelines established in
recognized international standards and national regulations
across the globe. It is widely recognized that small device
modiﬁcations can sometimes have large effects (positive
or negative) and that the structured process contained in
the international standards ensures potential effects are
fully evaluated. This process for evaluating device modiﬁca-
tions aims to ensure that the physician can have the same
level of conﬁdence in the safety and performance of the
modiﬁed device as was present for the original unmodiﬁed
device.
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